Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e318191520c